“French drug developer Genfit (Euronext: $GNFT) is planning to list itself in the United States as its drug elafibranor continues to be evaluated in a late-stage study for the so far untreated fatty liver disease...”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.